to cause less pain after injection than the parenteral forms of tetracycline hydrochloride and tetracycline phosphate complex.
"Tetrex P M T", the product under investigation for treatment reactions and therapeutic effects, contains pyrrolidinomethyl tetracycline nitrate equivalent to pyrrolidinomethyl tetracycline 350 mg., lignocaine hydrochloride 40 mg., ascorbic acid 575 mg., and magnesium gluconate 253 mg.; it was reconstituted with 2 ml. water for injection.
Methods
The initial diagnosis of non-specific urethritis was based on appearances in Gram-stained urethral smears; but additionally swabs of urethral secretion were sent in Stuart's transport medium to two laboratories where they were cultured for N. gonorrhoeae and Trichomonas vaginalis. Patients diagnosed as suffering from nonspecific urethritis were given one injection (2 ml.) of the tetracycline preparation immediately and a second 24 hours later. They were requested to return for surveillance on Day 4 or 5, at which time the prostate was examined; if material was obtainable, smears and cultures were taken, as on Days 8, 15, 22, and 29, and *Received for publication May 8, 1968. fortnightly thereafter for up to 3 months after treatment. Patients expecting to-leave the locality within 2 weeks were excluded from the investigation. A total of 101 male patients was included in the study.
Results

Treatment Reactions
23 (24.2 per cent.) of the 95 patients returning after the first injection complained of treatment reactions (Table I) . Pain was the most notable reaction; this varied in intensity from moderate to severe and was in some cases so severe as to make the patient refuse a second injection. No patient who received the second injection made any complaint of pain. 43 had suffered 59 previous episodes of non-specific urethritis between them. The contacts of sixty patients were unknown casual acquaintances, seventeen were friends, and seven were wives.
The follow-up after treatment is set out in Table  II . Twenty patients completed the 3 months' surveillance satisfactorily; forty had defaulted before this time but when clinically satisfactory.
In five cases the urethritis never cleared. Three of these patients had prostatitis, and two uncomplicated urethritis, one of whom had continued to drink alcohol very heavily. There were 24 cases of recurrence of urethritis all within 2 months of treatment.
Re-infection after further sexual intercourse accounted for 11, including the two cases of gonorrhoea; four of these had taken alcohol. There were thirteen cases of relapse; ten of these patients admitted taking alcohol. Discussion Reactions to treatment were noted by 23 (24*2 per cent.) of the 95 patients who returned after their first injection; nineteen (20 per cent.) complained of pain which varied from moderate to severe, and this is a problem which has to be overcome as it was a cause of default, although it was not so serious as that experienced with earlier intramuscular tetracyclines. No patient complained of any complications after the second injection, not even those who had complained of severe pain after the first. There was no evidence that the drug itself was concerned in the other reactions, which could indeed have followed any injection.
With regard to the four patients rejected from the investigation because of the later culture findings of gonorrhoea, one had a prostatitis and the organisms reappeared on Day 7; three patients had uncomplicated gonococcal urethritis, of whom two were cured by their two injections of Tetrex P M T while one relapsed on Day 4 and was cured with penicillin.
Twelve of the patients with non-specific urethritis received one injection only. Of these, six returned for follow-up; the urethritis cleared in three and they completed their surveillance satisfactorily, and the other three relapsed. All these had taken alcohol and one of them admitted re-exposure to risk of infection.
It is difficult to assess the role of defaulters. In addition to the six patients who defaulted after one injection, a further nine defaulted within 21 days of receiving their two injections. When last seen all were clinically satisfactory. There has been no history of their further attendance at any of the local clinics. The possibility is that most were cured, though this cannot be assumed.
All the recurrences developed within 2 months of treatment. Eleven patients admitted further exposure to risk of infection and ten others admitted taking alcohol, which is clear evidence of their indifference to repeated warnings to avoid both. All the recurrences which appeared more than one month after the initial clearing of the urethritis followed further sexual intercourse. Of the patients with non-specific prostatitis, four out of six relapsed, all by Day 8, two of them after taking alcohol; one patient had two further relapses after treatment with oral tetracyclines. It would therefore appear that Tetrex P M T. in the dosage used was ineffective in the treatment of nonspecific prostatitis.
Summary
In a trial of pyrrolidinomethyl tetracycline nitrate (Tetrex P M T), 101 male patients diagnosed by microscopy as suffering from non-specific urethritis were started on a course of two Trois des six malades recevant une injection avaient rechute. 24 des 84 qui avaient recu les deux injections n'avaient pas repondu au traitement ou avaient eu une rechute de l'uretrite non-sp6cifique, tous pendant les deux mois qui avaient suivi le traitement. Onze malades y compris deux qui avaient contracte la blennorragie avaient admis qu'ils s'etaient exposes de nouveau au risque d'une infection, et dix autres avaient admis qu'ils avaient pris de l'alcool.
Si l'echec au traitement est considere comme un echec de repondre ou comme une rechute sans reexposition pendant deux semaines apres que l'uretrite avait disparu alore seulement 5 (6,4 pour cent) des 78 malades atteints d'uretrite non-specifique sans complications avaient rechute. Ce resultat est plus favorable que celui rapporte apres le traitement par la tetracycline par voie buccale.
Quatre des six malades atteints de prostatite nonspecifique avaient rechute et il semblerait qu'une posologie plus forte serait indiquee dans ces cas.
